Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference
Rhea-AI Summary
Praxis Precision Medicines (NASDAQ: PRAX) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company, which focuses on developing therapies for central nervous system (CNS) disorders, will present a corporate overview at the conference on January 15, 2025, at 2:15pm PST at the Westin St. Francis Hotel in San Francisco.
The presentation will be accessible through a live webcast, and a replay will remain available for 30 days through the company's website at www.praxismedicines.com in the Investors + Media section under 'Upcoming & Recent Events'.
Positive
- None.
Negative
- None.
News Market Reaction – PRAX
In the trading session that priced this news, PRAX declined 3.26%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be presenting a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA at the Westin St. Francis Hotel on Wednesday, January 15, 2025 at 2:15pm PST.
A live webcast of the event will be available through this link. A replay of the event will also be available through the “Upcoming & Recent Events” page of the Investors + Media section of the company’s website at www.praxismedicines.com, for 30 days.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
